Search research articles
Contact Us
Filters
Showing results (151-160 of 216) with videos related to
Page
of 22
Sort By:
Biorxiv : the Preprint Server for Biology
|
July 15, 2024
Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome
Yujie Jiang, Matthew D Montierth, Kaixian Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Cancer Research Communications
|
August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Matthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Blood Advances
|
October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
Nitin Jain, Jayastu Senapati, Beenu Thakral, et al.
Cancer Cell
|
August 28, 2017
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L Carstens, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
Nature Communications
|
November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
Matthew T Campbell, Surena F Matin, Alda L Tam, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
Science Translational Medicine
|
April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Research Square
|
November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 216) with videos related to
Sort By:
Page
of 22
Biorxiv : the Preprint Server for Biology
|
July 15, 2024
Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome
Yujie Jiang, Matthew D Montierth, Kaixian Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 13, 2019
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando, Anu Sharma, Maria Gisela Higa, et al.
Cancer Research Communications
|
August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Matthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Blood Advances
|
October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
Nitin Jain, Jayastu Senapati, Beenu Thakral, et al.
Cancer Cell
|
August 28, 2017
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L Carstens, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
Nature Communications
|
November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
Matthew T Campbell, Surena F Matin, Alda L Tam, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
Science Translational Medicine
|
April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Research Square
|
November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Page
of 22